Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Cost of product revenue | 38,118 | 54,757 | 71,861 | 108,463 |
| Gross profit | 86,277 | 67,227 | 167,027 | 128,323 |
| OPERATING EXPENSES: | ||||
| Research and development | 6,014 | 1,031 | 8,611 | 1,858 |
| Plasma center operating expenses | 1,026 | 1,152 | 2,088 | 2,438 |
| Amortization of intangible assets | 55 | 32 | 110 | 57 |
| Gain on sale of plasma centers | - | - | (7,980) | - |
| Selling, general and administrative | 26,737 | 22,214 | 53,479 | 46,292 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's R&D?
- ADMA Biologics (ADMA) reported R&D of $6.01M in Q2 2026.
- How has ADMA Biologics's R&D changed year-over-year?
- ADMA Biologics's R&D increased by 483.3% year-over-year, from $1.03M to $6.01M.
- What is the long-term trend for ADMA Biologics's R&D?
- Over 4 years (2021 to 2025), ADMA Biologics's R&D has grown at a 6.9% compound annual growth rate (CAGR), from $3.65M to $4.76M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about ADMA Biologics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude